A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

(2013) R. Wendel Naumann et al.   JOURNAL OF CLINICAL ONCOLOGY

Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid

(2010) Iontcho R. Vlahov et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2010) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Pharmacokinetics and Exposure-Toxicity Relationship of a Folate-VincaAlkaloid Conjugate EC145 in Cancer Patients

(2009) Jing Li et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes

(2009) Y Sawada   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Folate receptor alpha as a tumor target in epithelial ovarian cancer

(2008) Kimberly R. Kalli et al.   GYNECOLOGIC ONCOLOGY

Rationale for folate receptor alpha targeted therapy in “high risk” endometrial carcinomas

(2008) Monica Brown Jones et al.   INTERNATIONAL JOURNAL OF CANCER